{"nct_id":"NCT03183492","title":"Immunogenicity and Persistence of GlaxoSmithKline (GSK) Biologicals' Havrix® in Healthy Adult Subjects Vaccinated at Infancy Under the Hepatitis A Universal Mass Vaccination (UMV) Program in Israel","status":"WITHDRAWN","status_verified_date":"2018-03","start_date":"2018-05-07","start_date_type":"ESTIMATED","primary_completion_date":"2019-01-28","primary_completion_date_type":"ESTIMATED","completion_date":"2019-01-28","completion_date_type":"ESTIMATED","phases":["PHASE4"],"tickers":["GSK"]}